Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Allergan Pharmaceuticals International Limited manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners across 4 distinct art units. ROZOF, TIMOTHY R is the busiest examiner for this portfolio, holding 1 pending office action. The distribution of 4 pending office actions across 4 distinct examiners suggests that each matter is being reviewed by a different individual in a different technical group.
The involvement of 4 distinct art units indicates that the company's innovations span several technical sub-fields. This variety requires a prosecution strategy that can adapt to different art unit norms and examiner styles. With 4 distinct examiners involved, the company can observe a range of examiner behaviors, even though TIMOTHY R ROZOF is the only one identified as the busiest with 1 pending office action. This decentralized approach reduces the impact of any single examiner's perspective on the overall portfolio.
Practitioners should note that the Biotechnology & Pharmaceuticals technology area often requires navigating specific biological standards. Having 4 pending office actions across 4 distinct art units provides a broader view of how the USPTO perceives the company's technical disclosures. While the portfolio is currently managed by 4 distinct examiners, the coordination of these matters is essential to maintain consistency. The current data reflects an active engagement across multiple technical groups within the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.3% |
| FONTAINHAS, AURORA M | 1 | 37.8% | +49.4% |
| METCALF, MATTHEW CURRAN | 1 | 37.5% | +71.4% |
| AUDET, MAURY A | 1 | 50.1% | +23.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998763 | COMPOSITIONS COMPRISING TROPOELASTIN CROSSLINKED TO HYALURONIC ACID AND THE METHODS OF USE THEREOF | METCALF, MATTHEW CURRAN | 71d overdue |
| 18768496 | TREATMENT OF MIGRAINE | ROZOF, TIMOTHY R | — |
| 18640418 | FORMATION OF BONE | FONTAINHAS, AURORA M | — |
| 17637799 | TROPOELASTIN FOR USE IN TREATMENT OF ACNE SCARRING | AUDET, MAURY A | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1675 | 1 |
| 1647 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18768496 | TREATMENT OF MIGRAINE | ROZOF, TIMOTHY R | 1625 | §103DP | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18640418 | FORMATION OF BONE | FONTAINHAS, AURORA M | 1675 | §102§103§112DP | Non-Final OA | — | Pending | Apr 19, 2024 |
| 17998763 | COMPOSITIONS COMPRISING TROPOELASTIN CROSSLINKED TO HYALURONIC ACID AND THE METHODS OF USE THEREOF | METCALF, MATTHEW CURRAN | 1647 | §103DP | Non-Final OA | 71d overdue | Pending | Nov 14, 2022 |
| 17637799 | TROPOELASTIN FOR USE IN TREATMENT OF ACNE SCARRING | AUDET, MAURY A | 1654 | §103 | Final Rejection | — | Pending | Feb 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAllergan Pharmaceuticals International Limited has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Timothy R Rozof has the most, with 1 of Allergan Pharmaceuticals International Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
